BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ozieranski P, Csanadi M, Rickard E, Tchilingirian J, Mulinari S. Analysis of Pharmaceutical Industry Payments to UK Health Care Organizations in 2015. JAMA Netw Open 2019;2:e196253. [PMID: 31225896 DOI: 10.1001/jamanetworkopen.2019.6253] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Ozieranski P, Rickard E, Mulinari S. Exposing drug industry funding of UK patient organisations. BMJ 2019;365:l1806. [PMID: 31122928 DOI: 10.1136/bmj.l1806] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 6.7] [Reference Citation Analysis]
2 Ozaki A, Saito H, Senoo Y, Sawano T, Shimada Y, Kobashi Y, Yamamoto K, Suzuki Y, Tanimoto T. Overview and transparency of non-research payments to healthcare organizations and healthcare professionals from pharmaceutical companies in Japan: Analysis of payment data in 2016. Health Policy 2020;124:727-35. [DOI: 10.1016/j.healthpol.2020.03.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
3 Yamamoto K, Murayama A, Ozaki A, Saito H, Sawano T, Tanimoto T. Financial conflicts of interest between pharmaceutical companies and the authors of urology clinical practice guidelines in Japan. Int Urogynecol J 2021;32:443-51. [PMID: 33151353 DOI: 10.1007/s00192-020-04547-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Mulinari S, Martinon L, Jachiet PA, Ozieranski P. Pharmaceutical industry self-regulation and non-transparency: country and company level analysis of payments to healthcare professionals in seven European countries. Health Policy 2021;125:915-22. [PMID: 34006392 DOI: 10.1016/j.healthpol.2021.04.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Rickard E, Ozieranski P. A hidden web of policy influence: The pharmaceutical industry's engagement with UK's All-Party Parliamentary Groups. PLoS One 2021;16:e0252551. [PMID: 34166396 DOI: 10.1371/journal.pone.0252551] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Murayama A, Senoo Y, Harada K, Kotera Y, Saito H, Sawano T, Suzuki Y, Tanimoto T, Ozaki A. Awareness and Perceptions among Members of a Japanese Cancer Patient Advocacy Group Concerning the Financial Relationships between the Pharmaceutical Industry and Physicians. Int J Environ Res Public Health 2022;19:3478. [PMID: 35329160 DOI: 10.3390/ijerph19063478] [Reference Citation Analysis]
7 Ozieranski P, Martinon L, Jachiet PA, Mulinari S. Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: a European policy review. BMJ Open 2021;11:e053138. [PMID: 34916317 DOI: 10.1136/bmjopen-2021-053138] [Reference Citation Analysis]
8 Ozieranski P, Csanádi M, Rickard E, Mulinari S. Under-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012-2016). BMJ Open 2020;10:e037351. [PMID: 32950962 DOI: 10.1136/bmjopen-2020-037351] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
9 Mulinari S, Vilhelmsson A, Rickard E, Ozieranski P. Five years of pharmaceutical industry funding of patient organisations in Sweden: Cross-sectional study of companies, patient organisations and drugs. PLoS One 2020;15:e0235021. [PMID: 32579571 DOI: 10.1371/journal.pone.0235021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
10 Rickard E, Ozieranski P, Mulinari S. Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK. Health Policy 2019;123:1244-50. [PMID: 31455562 DOI: 10.1016/j.healthpol.2019.08.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
11 Saghy E, Mulinari S, Ozieranski P. Drug company payments to General Practices in England: Cross-sectional and social network analysis. PLoS One 2021;16:e0261077. [PMID: 34874975 DOI: 10.1371/journal.pone.0261077] [Reference Citation Analysis]
12 Murayama A, Kamamoto S, Saito H, Yamada K, Bhandari D, Shoji I, Mamada H, Kawashima M, Yamashita E, Kusumi E, Sawano T, Sapkota B, Tanimoto T, Ozaki A. Pharmaceutical Payments to Japanese Board-Certified Infectious Disease Specialists: A Four-Year Retrospective Analysis of Payments from 92 Pharmaceutical Companies between 2016 and 2019. Int J Environ Res Public Health 2022;19:7417. [PMID: 35742661 DOI: 10.3390/ijerph19127417] [Reference Citation Analysis]
13 Moriarty F, Larkin J, Fahey T. Payments reported by the pharmaceutical industry in Ireland from 2015 to 2019: An observational study. Health Policy 2021;125:1297-304. [PMID: 34429238 DOI: 10.1016/j.healthpol.2021.07.016] [Reference Citation Analysis]
14 Ozaki A, Murayama A, Harada K, Saito H, Sawano T, Tanimoto T, Ozieranski P. How Do Institutional Conflicts of Interest Between Pharmaceutical Companies and the Healthcare Sector Become Corrupt? A Case Study of Scholarship Donations Between Department of Clinical Anesthesiology, Mie University, and Ono Pharmaceutical in Japan. Front Public Health 2021;9:762637. [PMID: 35047471 DOI: 10.3389/fpubh.2021.762637] [Reference Citation Analysis]
15 Ozaki A, Murayama A, Saito H, Sawano T, Harada K, Senoo Y, Yamamoto K, Tanimoto T. Transparency Is Not Enough: How Can We Improve the Management of Financial Conflicts of Interest Between Pharma and Healthcare Sectors? Clin Pharmacol Ther 2021;110:289-91. [PMID: 33377498 DOI: 10.1002/cpt.2126] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Torgerson T, Wayant C, Cosgrove L, Akl EA, Checketts J, Dal Re R, Gill J, Grover SC, Khan N, Khan R, Marušić A, McCoy MS, Mitchell A, Prasad V, Vassar M. Ten years later: a review of the US 2009 institute of medicine report on conflicts of interest and solutions for further reform. BMJ Evid Based Med 2020:bmjebm-2020-111503. [PMID: 33177167 DOI: 10.1136/bmjebm-2020-111503] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]